

IntelGenx Technologies Corp.  
Form 10-Q  
November 12, 2014

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934**

**For the quarterly period ended September 30, 2014 or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

**Commission File Number 000-31187**

**INTELGENX TECHNOLOGIES CORP.**

(Exact name of small business issuer as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**87-0638336**

(I.R.S. Employer Identification No.)

**6425 Abrams, Ville Saint Laurent, Quebec H4S 1X9, Canada**

(Address of principal executive offices)

**(514) 331-7440**

(Issuer's telephone number)

(Former Name, former Address, if changed since last report)

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, non-accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting

Smaller reporting company

company)

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes  No

APPLICABLE TO CORPORATE ISSUERS:

63,465,256 shares of the issuer's common stock, par value \$.00001 per share, were issued and outstanding as of November 7, 2014.

IntelGenx Technologies Corp.  
Form 10-Q

TABLE OF CONTENTS

<u>PART I. FINANCIAL INFORMATION</u>	<u>3</u>
<u>Item 1. Financial Statements</u>	<u>3</u>
<u>Consolidated Balance Sheet</u>	<u>4</u>
<u>Statement of Shareholders' Equity</u>	<u>5</u>
<u>Statement of Operations and Comprehensive Loss</u>	<u>6</u>
<u>Statement of Cash Flows</u>	<u>7</u>
<u>Notes to Financial Statements</u>	<u>8</u>
<u>Item 2. Management's Discussion and Analysis and Results of Operations</u>	<u>14</u>
<u>Item 3. Controls and Procedures</u>	<u>23</u>
<u>PART II. OTHER INFORMATION</u>	<u>23</u>
<u>Item 1. Legal Proceedings</u>	<u>23</u>
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>23</u>
<u>Item 3. Defaults upon Senior Securities</u>	<u>23</u>
<u>Item 4. Reserved</u>	<u>23</u>
<u>Item 5. Other Information</u>	<u>23</u>
<u>Item 6. Exhibits</u>	<u>24</u>
<u>Signatures</u>	<u>24</u>

**IntelGenx Technologies Corp.**

**Consolidated Interim Financial Statements**

**September 30, 2014**

**(Expressed in U.S. Funds)**

**(Unaudited)**

**Contents**

<u>Consolidated Balance Sheet</u>	<u>4</u>
<u>Consolidated Statement of Shareholders' Equity</u>	<u>5</u>
<u>Consolidated Statement of Comprehensive Loss</u>	<u>6</u>
<u>Consolidated Statement of Cash Flows</u>	<u>7</u>
<u>Notes to Consolidated Financial Statements</u>	<u>8 - 13</u>

**IntelGenx Technologies Corp.**  
**Consolidated Balance Sheet**  
(Expressed in Thousands of U.S. Dollars (\$000 s) Except Share and Per Share Data)  
(Unaudited)

	September 30, 2014	December 31, 2013
<b>Assets</b>		
<b>Current</b>		
Cash and cash equivalents	\$ 4,376	\$ 5,005
Accounts receivable	52	144
Prepaid expenses	75	133
Investment tax credits receivable	234	268
<b>Total Current Assets</b>	<b>4,737</b>	<b>5,550</b>
<b>Leasehold Improvements and Equipment, net</b>	<b>805</b>	<b>588</b>
<b>Intangible Assets (note 4)</b>	<b>53</b>	<b>79</b>
<b>Total Assets</b>	<b>\$ 5,595</b>	<b>\$ 6,217</b>
<b>Liabilities</b>		
<b>Current</b>		
Accounts payable and accrued liabilities	267	593
Deferred license revenue (note 5)	358	308
<b>Total Current Liabilities</b>	<b>625</b>	<b>901</b>
<b>Deferred License Revenue, non-current portion (note 5)</b>	<b>77</b>	<b>308</b>
<b>Total Liabilities</b>	<b>702</b>	<b>1,209</b>
<b>Shareholders' Equity</b>		
<b>Capital Stock (note 6)</b>	<b>1</b>	<b>1</b>
<b>Additional Paid-in-Capital</b>	<b>22,635</b>	<b>20,934</b>
<b>Accumulated Deficit</b>	<b>(17,592)</b>	<b>(16,102)</b>
<b>Accumulated Other Comprehensive Income</b>	<b>(151)</b>	<b>175</b>
<b>Total Shareholders' Equity</b>	<b>4,893</b>	<b>5,008</b>
	<b>\$ 5,595</b>	<b>\$ 6,217</b>

See accompanying notes

**Approved on Behalf of the Board:**

*/s/ Bernd Melchers* Director

*/s/ Horst G. Zerbe* Director

**IntelGenx Technologies Corp.****Consolidated Statement of Shareholders' Equity****For the Period Ended September 30, 2014****(Expressed in Thousands of U.S. Dollars (\$000 s) Except Share and Per Share Data)****(Unaudited)**

	Capital Stock		Additional	Accumulated	Accumulated	Total
	Number	Amount	Paid-In	Deficit	Other	Shareholders'
			Capital		Comprehensive	Equity
					Profit (Loss)	
<b>Balance - December 31, 2013</b>	60,984,267	\$ 1	\$ 20,934	\$ (16,102)	\$ 175	\$ <b>5,008</b>
Foreign currency translation adjustment	-	-	-	-	(326)	<b>(326)</b>
Warrants exercised (note 7)	2,480,988	-	1,619	-	-	<b>1,619</b>
Stock-based compensation (note 7)	-	-	82	-	-	<b>82</b>
Net loss for the period	-	-	-	(1,490)	-	<b>(1,490)</b>
<b>Balance September 30, 2014</b>	<b>63,465,255</b>	<b>\$ 1</b>	<b>\$ 22,635</b>	<b>\$ (17,592)</b>	<b>\$ (151)</b>	<b>\$ 4,893</b>

See accompanying notes

**IntelGenx Technologies Corp.****Consolidated Statement of Comprehensive Loss****(Expressed in Thousands of U.S. Dollars (\$000 s) Except Share and Per Share Data)****(Unaudited)**

	For the Three-Month Period Ended September 30,		For the Nine-Month Period Ended September 30,	
	2014	2013	2014	2013
<b>Revenues</b>				
Royalties	\$ 129	\$ 28	\$ 310	\$ 119
License and other revenue	323	72	524	685
<b>Total Revenues</b>	<b>452</b>	<b>100</b>	<b>834</b>	<b>804</b>
<b>Expenses</b>				
Research and development expense	359	191	772	406
Selling, general and administrative expense	521	491	1,524	1,341
Depreciation of tangible assets	11	7	25	24
Amortization of intangible assets	6	10	26	29
<b>Total Costs and Expenses</b>	<b>897</b>	<b>699</b>	<b>2,347</b>	<b>1,800</b>
<b>Loss from Operations</b>	<b>(445)</b>	<b>(599)</b>	<b>(1,513)</b>	<b>(996)</b>
<b>Other Income</b>				
Interest and other income	11	-	23	1
<b>Total Other Income</b>	<b>11</b>	<b>-</b>	<b>23</b>	<b>1</b>
<b>Net Loss</b>	<b>(434)</b>	<b>(599)</b>	<b>(1,490)</b>	<b>(995)</b>
<b>Other Comprehensive Income (Loss)</b>				
Foreign currency translation adjustment	(256)	73	(326)	(33)
<b>Comprehensive Loss</b>	<b>\$ (690)</b>	<b>\$ (526)</b>	<b>\$ (1,816)</b>	<b>\$ (1,028)</b>
<b>Basic and Diluted Weighted Average Number of Shares Outstanding</b>	<b>63,465,255</b>	<b>52,687,253</b>	<b>63,133,545</b>	<b>52,474,772</b>
Basic and Diluted Loss Per Common Share (note 9)	\$ (0.01)	\$ (0.01)	\$ (0.03)	\$ (0.02)
See accompanying notes				

**IntelGenx Technologies Corp.****Consolidated Statement of Cash Flows****(Expressed in thousands of U.S. Dollars (\$000 s) Except Share and Per Share Data)****(Unaudited)**

	For the Three-Month Period Ended September 30,		For the Nine-Month Period Ended September 30,	
	2014	2013	2014	2013
<b>Funds Provided (Used) -</b>				
<b>Operating Activities</b>				
Net loss	\$ (434)	\$ (599)	\$ (1,490)	\$ (995)
Amortization and depreciation	17	17	51	53
Stock-based compensation	17	35	82	82
Changes in assets and liabilities:	(400)	(547)	(1,357)	(860)
Accounts receivable	1	305	92	1,227
Prepaid expenses	18	(128)	58	(120)
Investment tax credits receivable	(17)	56	34	1
Accounts payable and accrued liabilities	1	(23)	(326)	(745)
Deferred revenue	(77)	(74)	(180)	(228)
<b>Net change in assets and liabilities</b>	<b>(74)</b>	<b>136</b>	<b>(322)</b>	<b>135</b>
<b>Net cash used by operating activities</b>	<b>(474)</b>	<b>(411)</b>	<b>(1,679)</b>	<b>(725)</b>
<b>Financing Activities</b>				
Proceeds from exercise of warrants and stock options	-	714	1,619	1,496
<b>Net cash provided by financing activities</b>	<b>-</b>	<b>714</b>	<b>1,619</b>	<b>1,496</b>
<b>Investing Activities</b>				
Additions to leasehold improvements and equipment	(106)	(99)	(274)	(260)
<b>Net cash used in investing activities</b>	<b>(106)</b>	<b>(99)</b>	<b>(274)</b>	<b>(260)</b>
<b>Increase (Decrease) in Cash and Cash Equivalents</b>	<b>(580)</b>	<b>204</b>	<b>(334)</b>	<b>511</b>
<b>Effect of Foreign Exchange on Cash and Cash Equivalents</b>	<b>(222)</b>	<b>63</b>	<b>(295)</b>	<b>(19)</b>



<b>Beginning of Period</b>	<b>5,178</b>		2,284		<b>5,005</b>		2,059
<b>End of Period</b>	\$ <b>4,376</b>	\$	2,551	\$	<b>4,376</b>	\$	2,551

See accompanying notes

**IntelGenx Technologies Corp.**

**Notes to Consolidated Interim Financial Statements**

**September 30, 2014**

**(Expressed in U.S. Funds)**

**(Unaudited)**

**1. Basis of Presentation**

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature.

These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2013. Operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States ( U.S. GAAP ). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

The financial statements are expressed in U.S. funds.

Management has performed an evaluation of the Company's activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

**2. Adoption of New Accounting Standards  
Revenue Recognition and Disclosures**

The FASB issued Update No. 2013-04, Liabilities (Topic 405) Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date . The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU were applicable for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this Statement did not have a material effect on the Company's financial position or results of operations.

**IntelGenx Technologies Corp.**

**Notes to Consolidated Interim Financial Statements**

**September 30, 2014**

**(Expressed in U.S. Funds)**

**(Unaudited)**

**2. Adoption of New Accounting Standards (Cont d)**

The FASB issued Update No. 2013-05, Foreign Currency Matters (Topic 830) Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. The amendments in this Update resolve the diversity in practice about whether Subtopic 810-10, Consolidation Overall, or Subtopic 830-30, Foreign Currency Matters Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU were effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. The adoption of this Statement did not have a material effect on the Company's financial position or results of operations.

The FASB issued Update No. 2013-07, Presentation of Financial Statements Liquidation Basis of Accounting. The objective of this Update is to clarify when an entity should apply the liquidation basis of accounting and to provide principles for the measurement of assets and liabilities under the liquidation basis of accounting, as well as any required disclosures. These amendments were effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. The adoption of this Statement did not have a material effect on the Company's financial position or results of operations.

The FASB issued Update No. 2013-11, Income Taxes (Topic 740) Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The amendments were effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to all unrecognized tax benefits that exist at the effective date. The adoption of this Statement did not have a material effect on the Company's financial position or results of operations.

**3. Significant Accounting Policies**  
**Recently Issued Accounting Pronouncements**

ASU 2014-15, Presentation of Financial Statements Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern

The FASB has issued ASU No. 2014-15 which is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization's management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company

is currently evaluating the impact of this update on its consolidated financial statements.

**IntelGenx Technologies Corp.**

**Notes to Consolidated Interim Financial Statements**

**September 30, 2014**

**(Expressed in U.S. Funds)**

**(Unaudited)**

**3. Significant Accounting Policies (Cont d)**

ASU 2014-13, Consolidation (Topic 810): Measuring the Financial Assets and the Financial Liabilities of a Consolidated Collateralized Financing Entity

The FASB has issued ASU No. 2014-13 which will apply to a reporting entity that is required to consolidate a collateralized financing entity under the Variable Interest Entities guidance. The fair value of the financial assets of a collateralized financing entity, as determined under GAAP, may differ from the fair value of its financial liabilities even when the financial liabilities have recourse only to the financial assets. Before this ASU, there was no specific guidance in GAAP on how a reporting entity should account for that difference. The amendments in this ASU provide an alternative to Topic 820, Fair Value Measurement, for measuring the financial assets and the financial liabilities of a consolidated collateralized financing entity to eliminate that difference. The amendments in this ASU are effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted as of the beginning of an annual period. The adoption of ASU 2014-13 is not expected to have a material effect on the Company's financial position or results of operations.

ASU 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for shared-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period.

The FASB has issued ASU No. 2014-12 which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, *Compensation – Stock Compensation*, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption of ASU-2014-12 is not expected to have material effect on the Company's financial position or results of operations.

ASU No. 2014-09, Revenues from Contracts with Customers (Topic 606)

The FASB and IASB (the Boards) have issued converged standards on revenue recognition. ASU No. 2014-09 affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. This ASU will supersede the revenue recognition requirements in Topic 605, *Revenue Recognition* and most industry-specific guidance. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

**IntelGenx Technologies Corp.**

**Notes to Consolidated Interim Financial Statements**

**September 30, 2014**

**(Expressed in U.S. Funds)**

**(Unaudited)**

**3. Significant Accounting Policies (Cont d)**

- Step 1: Identify the contract(s) with a customer.
- Step 2: Identify the performance obligations in the contract.
- Step 3: Determine the transaction price.
- Step 4: Allocate the transaction price to the performance obligations in the contract.
- Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. This ASU is to be applied retrospectively, with certain practical expedients allowed. Early application is not permitted. The Company is currently evaluating the impact of this update on its consolidated financial statements.

ASU No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity

The FASB has issued ASU No. 2014-08 which enhance convergence between U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in the ASU change the criteria for reporting discontinued operations while enhancing disclosures in this area. It also addresses sources of confusion and inconsistent application related to financial reporting of discontinued operations guidance in U.S. GAAP. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization's operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in the ASU are effective in the first quarter of 2015 for public organizations with calendar year ends. Early adoption is permitted. The adoption of ASU-2014-08 is not expected to have material effect on the Company's financial position or results of operations.

**4. Intangible Assets**

As of September 30, 2014 NDA acquisition costs of \$53 thousand (December 31, 2013 - \$79 thousand) were recorded as intangible assets on the Company's balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL®. The asset is being amortized over its estimated useful life of 39 months. The Company commenced amortization upon commercial launch of the product in October 2012.

**IntelGenx Technologies Corp.****Notes to Consolidated Interim Financial Statements****September 30, 2014****(Expressed in U.S. Funds)****(Unaudited)****5. Deferred License Revenue**

Deferred license revenue represents upfront payments received for the granting of licenses to the Company's patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.

Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of \$1 million, which the Company recognized as deferred license revenue. The deferred license revenue is being amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL® are expected to be exclusive.

In January, 2014 IntelGenx entered into a development and commercialization agreement with Par Pharmaceutical, Inc. for two products. The Company received \$100 thousand upon execution of the agreement, of which \$50 thousand has been recognized as deferred revenue until certain development milestones have been achieved.

As a result of this policy, the Company has a deferred revenue balance of \$435 thousand at September 30, 2014 (December 31, 2013 - \$616 thousand) that has not been recognized as revenue.

**6. Capital Stock**

	<b>September 30, 2014</b>	<b>December 31, 2013</b>
Authorized -		
100,000,000 common shares of \$0.00001 par value		
20,000,000 preferred shares of \$0.00001 par value		
Issued -		
63,465,255 (December 31, 2013 - 60,984,267) common shares	\$ 635	\$ 610

**IntelGenx Technologies Corp.**

**Notes to Consolidated Interim Financial Statements**

**September 30, 2014**

**(Expressed in U.S. Funds)**

**(Unaudited)**

**7. Additional Paid-In Capital**

**Stock options**

No stock options were exercised during the nine month period ended September 30, 2014. During the nine month period ended September 30, 2013 a total of 75,000 stock options were exercised for 75,000 common shares having a par value of \$0 thousand in aggregate, for cash consideration of \$31 thousand, resulting in an increase in additional paid-in capital of \$31 thousand.

Compensation expenses for stock-based compensation of \$82 thousand and \$82 thousand were recorded during the nine month periods ended September 30, 2014 and 2013 respectively. The entire amount expensed in 2014 relates to stock options granted to employees and directors. Of the amount expensed in 2013, \$67 thousand relates to stock options granted to employees and directors and \$15 thousand relates to options granted to independent third party consultants. As at September 30, 2014 the Company has \$56 thousand (2013 - \$202 thousand) of unrecognized stock-based compensation.

**Warrants**

During the nine month period ended September 30, 2014 a total of 2,480,988 (2013 - 3,098,500) warrants were exercised for 2,480,988 (2013 - 3,098,500) common shares having a par value of \$0 thousand in aggregate, for cash consideration of \$1,619 thousand (2013 - \$1,465 thousand), resulting in an increase in additional paid-in capital of \$1,619 thousand (2013 - \$1,465 thousand).

**8. Related Party Transactions**

Included in management salaries are \$30 thousand (2013 - \$8 thousand) for options granted to the Chief Executive Officer, \$Nil (2013 - \$24 thousand) for options granted to the Chief Operating Officer, \$33 thousand (2013 - \$19 thousand) for options granted to the Chief Financial Officer and \$11 thousand (2013 - \$8 thousand) for options granted to non-employee directors, with all options being granted under the 2006 Stock Option Plan.

Also included in management salaries are director fees of \$139 thousand (2013 - \$63 thousand) for attendance to board meetings and audit committee meetings.

In addition, during the first nine months of 2013 the Company paid \$66 thousand in fees to a director under a management consultancy agreement. No such fees were paid during the first nine months of 2014.

The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

**9. Basic and Diluted Loss Per Common Share**

Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive.





## **Item 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

### **Introduction to management's discussion and analysis**

The purpose of this section, Management's Discussion and Analysis of Financial Condition and Results of Operations, is to provide a narrative explanation of the financial statements that enables investors to better understand the business of the Company, to enhance the Company's overall financial disclosures, to provide the context within which the Company's financial information may be analyzed, and to provide information about the quality of, and potential variability of, the Company's financial condition, results of operations and cash flows. Unless otherwise indicated, all financial and statistical information included herein relates to continuing operations of the Company. Unless otherwise indicated or the context otherwise requires, the words, IntelGenx, Company, we, us, and our refer to IntelGenx Technologies Corp. and its subsidiaries, including IntelGenx Corp. This information should be read in conjunction with the accompanying unaudited Consolidated Financial Statements and Notes thereto.

### **Company background**

We are a drug delivery company established in 2003 and headquartered in Montreal, Quebec, Canada. Our focus is on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Our business strategy is to develop pharmaceutical products based on our proprietary drug delivery technologies and, once the viability of a product has been demonstrated, to license the commercial rights to partners in the pharmaceutical industry. In certain cases, we rely upon partners in the pharmaceutical industry to fund development of the licensed products, complete the regulatory approval process with the U.S. Food and Drug Administration (FDA) or other regulatory agencies relating to the licensed products, and assume responsibility for marketing and distributing such products.

In addition, we may choose to pursue the development of certain products until the project reaches the marketing and distribution stage. We will assess the potential for successful development of a product and associated costs, and then determine at which stage it is most prudent to seek a partner, balancing such costs against the potential for additional returns earned by partnering later in the development process.

We have also undertaken a strategy under which we will work with pharmaceutical companies in order to develop new dosage forms for pharmaceutical products for which patent protection is nearing expiration. Under §(505)(b)(2) of the Food, Drug, and Cosmetics Act, the FDA may grant market exclusivity for a term of up to three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials, other than bioavailability studies, conducted by or for the sponsor.

We are continuing to develop the existing products in our pipeline and may also perform research and development on other potential products as opportunities arise.

We currently purchase and/or lease, on an as-needed basis, the equipment necessary for performing research and development activities related to our products.

We plan to hire new personnel, primarily in the areas of research and development, manufacturing, and administration on an as-needed basis as we enter into partnership agreements, establish our pilot plant VersaFilm manufacturing capability, and increase our research and development activities.

## **Key developments**

### ***Anti-migraine VersaFilm product***

On February 4, 2014, together with our co-development partner RedHill Biopharma Ltd. ("RedHill") (IntelGenx and RedHill together, the Companies), we announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the New Drug Application ("NDA") for our VersaFilm product for the treatment of acute migraines. The anti-migraine VersaFilm product is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT<sub>1</sub> receptor agonist and the active drug in Merck & Co.'s Maxalt®. The questions raised by the FDA in the CRL regarding the NDA for the anti-migraine VersaFilm product primarily relate to Chemistry, Manufacturing and Controls ("CMC") and to the packaging and labeling of the product.

On March 3, 2014 the Companies announced the submission of a response to the FDA's CRL and on April 24, 2014 the Companies reported that the FDA had acknowledged receipt of our response and has requested additional CMC data, which the Companies believe they can supply based on available information. The Companies further reported that the supplier of the active pharmaceutical ingredient (API) of the product is currently holding compliance discussions with the FDA following a temporary import ban of the API. These discussions are independent of RedHill and IntelGenx and are not specific to our anti-migraine VersaFilm product. The Companies are diligently working on a variety of options to ensure continued supply of the raw material regardless of the result of these compliance discussions and have already identified and audited an alternative active pharmaceutical ingredient (API) supplier.

On April 28, 2014 the Companies announced the commencement of a comparative bioavailability clinical study comparing the anti-migraine VersaFilm product to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application and follows a positive scientific advice meeting with the German Federal Institute for Drugs and Medical Devices announced by RedHill in November 2013.

On May 21, 2014 the Companies announced positive results from the comparative bioavailability study.

Subsequent to the end of the quarter, on October 1, 2014 the Companies announced that they have submitted a Marketing Authorization Application ("MAA") to the German Federal Institute for Drugs and Medical Devices ("BfArM") seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT®. The brand name RIZAPORT® was also conditionally approved by the FDA as part of the NDA review process in the U.S.

### ***Par Pharmaceutical, Inc.***

On January 13, 2014 we announced the execution of a second development and commercialization agreement with Par Pharmaceutical, Inc. ("Par") for two new products utilizing our proprietary oral drug delivery platforms.

Under the terms of the agreement, Par has obtained certain exclusive rights to market and sell our products in the USA. In exchange we received an upfront payment and will receive milestone payments, together with a share of the profits upon commercialization. In accordance with confidentiality clauses contained in the agreement, the specifics of the products and the financial terms remain confidential.

### ***Erectile Dysfunction VersaFilm product***

On February 24, 2014 we announced the completion of a pilot biostudy with our proprietary VersaFilm tadalafil product for erectile dysfunction that indicated bioequivalence with the leading brand reference listed drug (RLD) tadalafil product.



This was a randomized, two-period, two-way crossover study in healthy male subjects. The study was designed to determine whether VersaFilm<sup>®</sup> tadalafil was bioequivalent as measured by industry standard pharmacokinetic measures of peak plasma concentration (C<sub>max</sub>) and area under the curve (AUC). The study results demonstrated that VersaFilm<sup>®</sup> tadalafil was within an acceptable range of bioequivalency with the RLD on both of these measures.

The successful outcome of this study enables us to finalize the optimization of the formulation and subsequently move on to pivotal activities.

#### ***Government Funding for CNS VersaFilm<sup>®</sup> product***

On April 30, 2014 we announced financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition to advisory services and technological expertise, the funding provided by NRC-IRAP will support further development of a product for the treatment of central nervous system (CNS) diseases and disorders. The product will be based upon our proprietary, oral thin film, VersaFilm<sup>®</sup>, technology.

Subsequent to the end of the quarter, on November 3, 2014 we announced the successful completion of a pilot clinical study for INT0036 that demonstrated a significantly improved pharmacokinetic profile against the reference product. The study data confirm that buccal absorption of the drug from the INT0036 film product results in a significantly higher bioavailability of the drug compared to oral tablets. Therapeutically relevant plasma concentrations are therefore reached significantly faster with the VersaFilm<sup>®</sup> product compared to conventional tablets. We also announced that the product, INT0036, is indicated for the treatment of schizophrenia.

In order to maintain our competitive advantage, we are unable to disclose further details related to this project at this time.

#### ***U.S. patent allowances***

On February 26, 2014 we announced receipt of a Notice of Allowance ("NOA") from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No. 11/647,033 entitled "Multilayer tablet" which covers the technology used in our hypertension product currently under development. A second NOA has been received for U.S. Patent Application Serial No. 11/782,838 entitled "Controlled-release pharmaceutical tablets" which is related to the drug delivery technology used in Forfivo XL<sup>®</sup>, our first FDA-approved product currently commercialized in the U.S. These two NOA's conclude the examination of each U.S. patent application and will result in the issuance of two U.S. patents after administrative processes are completed.

On April 16, 2014 we announced receipt of a further NOA from the USPTO for U.S. Patent Application Serial No. 12/836,810 entitled "Oral mucoadhesive dosage form" which covers IntelGenx' proprietary AdVersa<sup>®</sup> mucoadhesive drug delivery technology. This NOA concludes the examination of the U.S. patent application and will result in the issuance of a U.S. patent after the administrative process is completed.

#### ***Equity Analyst Coverage by H.C. Wainwright***

On July 1, 2014 we announced that H.C. Wainwright initiated equity analyst coverage of IntelGenx with a "buy" rating and price target of \$2. The stock closed at US\$0.70 on the OTCQX and at CAD\$0.74 on the TSX-V on Friday, June 27, 2014.

A copy of the initiation report can be accessed by clicking:

<https://hcwco.bluematrix.com/docs/pdf/ff51024b-71e2-47c5-ab58-7d05118ab4aa.pdf>.



All reports on us prepared by analysts represent the views of such analysts and are not necessarily those of IntelGenx. We are not responsible for the content, accuracy or timelines provided by analysts.

### Currency rate fluctuations

Our operating currency is Canadian dollars, while our reporting currency is U.S. dollars. Accordingly, our results of operations and balance sheet position have been affected by currency rate fluctuations. The following management discussion and analysis takes this into consideration whenever material. In summary, when comparing the currency rates used to prepare our financial statements for Q3, 2014 with the currency rates used to prepare the same period of the previous year, the strengthened US dollar results in an unrealized loss of approximately \$232 thousand on our cash position at September 30, 2014, but reduces our net loss from operations by approximately \$91 thousand for the nine month period ending September 30, 2014.

### Results of operations for the nine month period ended September 30, 2014 compared with the nine month period ended September 30, 2013.

In U.S.\$ thousands	2014	2013	Increase/ (Decrease)	Percentage Increase/ (Decrease)
Revenue	\$ 834	\$ 804	\$ 30	4%
Research and Development Expenses	772	406	366	90%
Selling, General and Administrative Expenses	1,524	1,341	183	14%
Depreciation of tangible assets	25	24	1	4%
Amortization of intangible assets	26	29	(3)	(10%)
<b>Net Loss</b>	<b>(1,490)</b>	<b>(995)</b>	<b>495</b>	<b>50%</b>
<b>Revenue</b>				

Total revenue increased from \$804 thousand in the first nine months of 2013 to \$834 thousand in the first nine months of 2014.

Of the total revenue recorded during the first nine months of 2014, \$534 thousand (2013: \$347 thousand) relates to Forfivo XL®, our first FDA approved product, which was launched in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP ( Edgemont ). Upon entering into the licensing agreement, Edgemont paid us an upfront fee of \$1 million, which we recognized as deferred license revenue. The deferred license revenue is being amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, we recognized \$230 thousand in income during the first nine months of 2014 (2013: \$230 thousand). In addition, in the nine months ended September 30, 2014 we recognized approximately \$304 thousand (2013: \$117 thousand) of royalty income earned from commercial sales of Forfivo XL®. Pursuant to the licensing agreement, royalty income is calculated as a percentage of net trade sales generated by Edgemont, is payable to us within 40 days of the end of each calendar quarter and recorded by us as income upon receipt.

Sales of Forfivo XL® have experienced significant quarterly growth in 2014 to date. Net trade sales in the second quarter of 2014 grew by 55% when compared with the previous quarter, and grew by a further 31% in Q3, 2014. Net trade sales in the third quarter of 2014 were more than double those recorded in the first quarter. Royalty income received in Q3, 2014 from sales of Forfivo XL® totaled \$127 thousand, compared with \$27 thousand received in the third quarter of 2013. Management anticipates that sales of Forfivo XL® will continue to grow at a significant rate.

Revenue for the nine months ended September 30, 2014 also includes an aggregate \$300 thousand (2013: \$457 thousand) in payments received for successfully achieving certain R&D development milestones for certain R&D development projects currently under development. We anticipate the receipt of further milestone payments as and when we successfully achieve further development milestones in accordance with contractual terms.

### **Research and development ( R&D ) expenses**

R&D expenses, net of R&D investment tax credits, totaled \$772 thousand in the nine months ended September 30, 2014, representing an increase of \$366 thousand to the amount of \$406 thousand expensed in the same period of 2013.

The increase in R&D expenses relates primarily to the costs incurred in the development of our second Par project, which is progressing according to plan, and also to the costs of a pilot clinical study for our VersaFilm product for erectile dysfunction that was completed in Q1, 2014 and that indicated bioequivalence with the leading brand reference listed drug tadalafil product.

Included within R&D expenses for the first nine months of 2014 are R&D Salaries of \$329 thousand, of which approximately \$6 thousand represents non-cash compensation. This compares with R&D salaries of \$427 thousand in the first nine months of 2013, of which approximately \$6 thousand represented non-cash compensation. The decrease in R&D salaries is primarily attributable to the fact that we ceased, with effect from December 31, 2013, to apportion 50% of the remuneration of our CEO to the R&D department.

In the nine months ended September 30, 2014 we recorded estimated research and development tax credits and refunds of \$63 thousand, compared with \$102 thousand that was recorded in the same period of the previous year. The amounts of research and development tax credits and refunds recorded by us may fluctuate from reporting period to reporting period depending upon the level of activity surrounding projects that we are currently progressing, together with whether or not we are able to fulfill Canadian eligibility criteria for obtaining such tax credits and refunds.

### **Selling, general and administrative ( SG&A ) expenses**

SG&A expenses totaled \$1,524 thousand in the first nine months of 2014, representing an increase of \$183 thousand compared with \$1,341 thousand in the first nine months of 2013.

The increase in SG&A expenses relates in part to an increase in legal expenses of approximately \$94 thousand primarily related to our Paragraph IV litigation with Wockhardt Bio AG ( Wockhardt ). In August 2013 we received a Paragraph IV Certification Letter from Wockhardt, advising of the submission of an Abbreviated New Drug Application ("ANDA") to the FDA requesting authorization to manufacture and market generic versions of Forfivo XL® ("Forfivo") 450 mg capsules in the United States. We continue to enforce our intellectual property rights for Forfivo XL®, which is currently protected by an issued patent listed in the FDA's Approved Drug Products List (Orange Book).

SG&A expenses increased by a further \$155 thousand for administrative and management salaries, due to the fact that we ceased to allocate 50% of the remuneration of our CEO to R&D expenses for fiscal 2014. SG&A expenses also increased by approximately \$80 thousand, due to the increase in the remuneration of our Board of Directors that was effective from April 1, 2014. However, as a result of management changes recently announced, we do not expect the increased rate of Board remuneration to continue. Increases in SG&A costs were partly compensated by a profit of approximately \$145 thousand (2013: \$16 thousand) realized on currency exchange, primarily from the conversion of US\$ to CAD\$.

Included in SG&A expenses are non-cash compensation expenses of approximately \$65 thousand (2013: \$53 thousand) from options granted to management employees in 2012 and 2013, \$11 thousand (2013: \$20 thousand) from options granted to non-employee directors in 2013, and \$Nil (2013: \$15 thousand) from options granted to



consultants in 2012.

**Depreciation of tangible assets**

In the nine months ended September 30, 2014 we recorded an expense of \$25 thousand for the depreciation of tangible assets, compared with an expense of \$24 thousand for the same period of the previous year. As at September 30, 2014 we are carrying approximately \$681 thousand of tangible assets, primarily VersaFilm manufacturing equipment, that are not being depreciated as they are not currently in service.

**Amortization of intangible assets**

The amortization of intangible assets expensed for the first nine months of 2014 totaled \$26 thousand, compared with \$29 thousand in the same period of last year. The expense relates to the amortization of NDA acquisition costs in respect of the final progress payment to acquire 100% ownership of Forfivo XL®. Commercialization of Forfivo XL® in October 2012 triggered amortization of the asset over its estimated useful life of 39 months.

**Share-based compensation expense, warrants and stock based payments**

Share-based compensation expense, warrants and share-based payments totaled \$82 thousand for the nine months ended September 30, 2014, compared with \$82 thousand for the nine months ended September 30, 2013.

We expensed approximately \$71 thousand in the first nine months of 2014 for options granted to our employees in 2012 and 2013 under the 2006 Stock Option Plan, and approximately \$11 thousand for options granted to non-employee directors in 2013, compared with \$59 thousand and \$8 respectively that was expensed in the same period of the previous year. We also expensed \$15 thousand in the first nine months of 2013 for options granted to consultants.

There remains approximately \$56 thousand in stock based compensation to be expensed in fiscal 2014 and 2015, all of which relates to the issuance of options to our employees and directors during 2012 and 2013. We anticipate the issuance of additional options and warrants in the future, which will continue to result in stock-based compensation expense.

**Key items from the balance sheet.**

In U.S.\$ thousands	September		Increase/ (Decrease)	Percentage Increase/ (Decrease)
	30, 2014	December 31, 2013		
Current Assets	\$ 4,737	\$ 5,550	\$ (813)	(15%)
Leasehold improvements and equipment	805	588	217	37%
Intangible Assets	53	79	(26)	(33%)
Accounts payable and accrued liabilities	267	593	(326)	(55%)
Deferred License Revenue	435	616	(181)	(29%)
Capital Stock	1	1	0	0%
Additional Paid-in-Capital	22,635	20,934	1,701	8%

## **Current assets**

Current assets totaled \$4,737 thousand at September 30, 2014 compared with \$5,550 thousand at December 31, 2013. The decrease of \$813 thousand is attributable to a decrease in cash and cash equivalents of approximately \$629 thousand, a decrease in accounts receivable of approximately \$92 thousand, a decrease in prepaid expenses of approximately \$58 thousand, and a decrease in investment tax credits receivable of approximately \$34 thousand.

## **Cash and cash equivalents**

Cash and cash equivalents totaled \$4,376 thousand as at September 30, 2014 representing a decrease of \$629 thousand compared with the balance of \$5,005 thousand as at December 31, 2013. The decrease in cash on hand relates to net cash used by operating activities of \$1,679 thousand, net cash used in investing activities of \$274 thousand, and an unrealized foreign exchange loss of \$295 thousand, partly offset with net cash provided by financing activities of \$1,619 thousand.

The unrealized foreign exchange loss of \$295 thousand relates to cash balances physically held in our operating currency of Canadian dollars being converted into our reporting currency of U.S. dollars.

The cash provided by financing activities derives from the exercise of 2,480,988 warrants that were exercised for 2,480,988 common shares for cash consideration of \$1,619 thousand.

## **Accounts receivable**

Accounts receivable totaled \$52 thousand as at September 30, 2014 representing a decrease of \$92 thousand compared with the balance of \$144 thousand as at December 31, 2013. The decreased balance relates to the payment of invoices in Q1, 2014 that were issued to clients and remained outstanding at December 31, 2013.

## **Prepaid expenses**

As of September 30, 2014 prepaid expenses totaled \$75 thousand compared with \$133 thousand as of December 31, 2013. The decrease in prepaid expenses primarily relates to a deposit paid in December 2013 for a biostudy undertaken in the first quarter of 2014, and a deposit paid in 2013 for R&D machinery that was to be supplied and installed in 2014.

## **Investment tax credits receivable**

R&D investment tax credits receivable totaled approximately \$234 thousand as at September 30, 2014 compared with \$268 thousand as at December 31, 2013. The decrease relates to the receipt in Q2, 2014 of \$106 thousand, being the balance of the fiscal 2012 investment tax credit receivable, which was partly offset by the accrual recorded for the first six months of 2014.

## **Leasehold improvements and equipment**

As at September 30, 2014, the net book value of leasehold improvements and equipment amounted to \$805 thousand, compared to \$588 thousand at December 31, 2013. In the nine months ended September 30, 2014 additions to assets totaled \$274 thousand and comprised \$53 thousand for pilot plant manufacturing equipment for our VersaFilm products, \$143 thousand for R&D equipment, \$69 thousand for leasehold improvements and \$9 thousand for computer equipment. In the nine months ended September 30, 2014 we recorded depreciation on leasehold improvements and equipment of \$25 thousand and incurred an unrealized foreign exchange loss of \$32 thousand.



As at September 30, 2014 we are carrying approximately \$681 thousand of tangible assets, primarily VersaFilm manufacturing equipment, that are not being depreciated as they are not currently in service.

### **Intangible assets**

As at September 30, 2014 NDA acquisition costs of \$53 thousand (December 31, 2013 - \$79 thousand) were recorded as intangible assets on our balance sheet and are related to the acquisition of 100% ownership of Forfivo XL®. The asset is being amortized over its expected useful life of 39 months and amortization commenced upon commercial launch of Forfivo XL® in the fourth quarter of 2012.

### **Accounts payable and accrued liabilities**

Accounts payable and accrued liabilities totaled \$267 thousand as at September 30, 2014 (December 31, 2013 - \$593 thousand) and consisted of approximately \$33 thousand relating to research and development activities, approximately \$89 thousand relating to professional fees, and approximately \$119 thousand relates to accrued payroll liabilities. This compares with approximately \$100 thousand relating to research and development activities, approximately \$180 thousand relating to professional fees, of which approximately \$87 thousand related to the public offering completed in December, 2013, and approximately \$301 thousand relating to accrued payroll liabilities, that was included in the accounts payable and accrued liabilities balance as at December 31, 2013.

### **Deferred license revenue**

Pursuant to the execution of a licensing agreement for Forfivo XL®, we received an upfront fee from Edgemont Pharmaceuticals in the first quarter of 2012, which we recognized as deferred license revenue. The deferred license revenue is being amortized in income over the period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, we have a deferred revenue balance related to this upfront fee of \$385 thousand at September 30, 2014 (December 31, 2013: \$616 thousand) that has not been recognized as revenue, of which \$77 thousand is recognized as the non-current portion and \$308 thousand is recognized in current assets as the current portion. This compares with \$308 thousand and \$308 thousand respectively as at December 31, 2013.

In January, 2014 IntelGenx entered into a development and commercialization agreement with Par Pharmaceutical, Inc. for two products. The Company received \$100 thousand upon execution of the agreement, of which \$50 thousand has been recognized in current liabilities as deferred revenue until certain development milestones that are expected to be achieved in 2014 have been realised.

### **Shareholders equity**

As at September 30, 2014 we had accumulated a deficit of \$17,592 thousand compared with an accumulated deficit of \$16,102 thousand as at December 31, 2013. Total assets amounted to \$5,595 thousand and shareholders equity totaled \$4,893 thousand as at September 30, 2014, compared with total assets and shareholders equity of \$6,217 thousand and \$5,008 thousand respectively, as at December 31, 2013.

### **Capital stock**

As at September 30, 2014 capital stock amounted to \$635 compared to \$610 at December 31, 2013. The increase reflects the issuance of 2,480,988 shares related to the exercise of warrants, with all shares issued at par value of \$0.00001. Capital stock is disclosed at its par value with the excess of proceeds shown in Additional paid-in-capital.

**Additional paid-in-capital**

Additional paid-in capital totaled \$22,635 thousand at September 30, 2014, compared with \$20,934 thousand at December 31, 2013. Additional paid-in capital increased by \$1,619 thousand for warrants exercised during the first quarter, and by \$82 thousand for stock based compensation attributable to the amortization of stock options granted to employees and directors.

**Taxation**

As at December 31, 2013, the date of our latest annual tax return, we had Canadian and provincial net operating losses of approximately \$8,874 thousand (2012: \$8,390 thousand) and \$9,040 thousand (2012: \$8,566 thousand) respectively, which may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2033. A portion of the net operating losses may expire before they can be utilized.

As at December 31, 2013, we had non-refundable tax credits of \$1,098 thousand (2012 - \$914 thousand) of which \$22 thousand is expiring in 2017, \$212 thousand is expiring in 2018, \$186 thousand is expiring in 2019, \$158 thousand is expiring in 2020, \$169 thousand is expiring in 2021, \$232 thousand is expiring in 2022 and \$119 thousand is expiring in 2023. We also had undeducted research and development expenses of \$4,354 thousand (2012: \$4,464 thousand) with no expiration date.

The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.

**Key items from the statement of cash flows**

In U.S.\$ thousands	September 30, 2014	September 30, 2013	Increase/ (Decrease)	Percentage Increase/ (Decrease)
Operating Activities	\$ (1,679)	\$ (725)	\$ 954	131%
Financing Activities	1,619	\$ 1,496	\$ 123	8%
Investing Activities	(274)	(260)	14	5%
Cash and cash equivalents - end of period	4,376	2,551	1,825	72%

**Statement of cash flows**

Net cash used by operating activities was \$1,679 thousand in the nine months ended September 30, 2014, compared with \$725 thousand for the nine months ended September 30, 2013. In the first nine months of 2014, net cash used by operating activities consisted of an operating loss of \$1,357 thousand (2013: \$860 thousand) net of non-cash related expenses of approximately \$133 thousand (2013: \$135 thousand), and a decrease in non-cash operating elements of working capital of \$322 thousand, compared with an increase of \$135 thousand in the same period of the previous year.

Operating activities will continue to consume our available funds until we are able to generate increased revenues.

The net cash provided by financing activities was \$1,619 thousand in the first nine months of 2014, compared with \$1,496 thousand provided in the same period of the previous year. The net cash provided in the first nine months of 2014 resulted from the exercise of 2,480,988 warrants, whereas the cash provided in the first nine months of 2013 resulted from the exercise of 3,098,500 warrants and 75,000 stock options.

Net cash used in investing activities amounted to \$274 thousand in the nine months ended September 30, 2014 compared with \$260 thousand in the nine months ended September 30, 2013. In the first nine months of 2014 we invested approximately \$53 thousand (2013: \$252 thousand) for pilot plant manufacturing equipment for our VersaFilm products, \$143 thousand (2013: \$5 thousand) for R&D equipment, \$69 thousand (2013: \$Nil) for leasehold improvements and \$9 thousand (2013: \$3 thousand) for computer equipment.

The balance of cash and cash equivalents as at September 30, 2014 amounted to \$4,376 thousand, compared with \$2,551 thousand at September 30, 2013.

#### **Off-balance sheet arrangements**

We have no off-balance sheet arrangements.

#### **Item 3. Controls and Procedures.**

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based upon that evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures are effective to cause the material information required to be disclosed by us in the reports that we file or submit under the Exchange Act to be recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. There have been no significant changes in our internal controls or in other factors which could significantly affect internal controls subsequent to the date we carried out our evaluation.

## **PART II**

#### **Item 1. Legal Proceedings**

This Item is not applicable

#### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

This Item is not applicable.

#### **Item 3. Defaults Upon Senior Securities**

This Item is not applicable.

#### **Item 4. (Reserved)**

#### **Item 5. Other Information**

This Item is not applicable.

